According to a new study, weight loss injections, including popular drugs such as Wegovy and Mounjaro, can provide protective shields for serious conditions such as dementia and stroke.
This study also suggests that an individual with a type 2 diabetes and obesity can face the reduction of the risk of early death.
After this study, scholars pointed out that the benefits of GLP agent drugs such as Semaglutide (found in Wegovy and Ozempic) and Tirzepatide (Mounjaro) are widely recognized for their weight and blood sugar levels, but the wider health benefits are still not understood.
Comprehensive research conducted by Taiwanese experts surveyed data from 60,000 people around the world and was diagnosed with type 2 diabetes and obesity.
About half of the participants received GLP agent drugs.
Such drugs function by suppressing appetite, slowing digestion, reducing liver sugar production, and improving insulin production of the body when necessary.
The other half used other anti -diabetic drugs.
During the seven -year follow -up period, researchers showed that those who provided GLP agent drugs had a 37 % lower risk of dementia and a 19 % reduction in stroke.
In addition, 30 % of the possibility of death during the subsequent period.
When researchers looked more data, they found a bigger advantage for people over 60 years old, women, and body mass index scores of 30 to 40.
They found that there was no difference between Parkinson’s bottles or brainwashing.
The academic community suggested that the drug’s “potential neurotrosis and brain vascular benefits” according to their research results, but demanded more research to confirm the results.
JAMA Network Open Journal said, “This discovery suggests that semagluide and Tirje fade can provide neuro protection and brain blood vessel benefits beyond blood sugar control, and improve the long -term cognition and survival of adults with type 2 diabetes and obesity.
According to this study, Tara Spires-Jones, a group leader of the University of Edinburgh and the UK Dementia Research Institute, said:
“This type of research cannot determine whether the drug directly protects the brain and reduces the risk of disease.
“Effectively treating type 2 diabetes and obesity is more likely to reduce the risk of dementia and stroke because the risk factors for these conditions are known.
“Diabetes and obesity patients require additional tasks, including random clinical trials, and other tests are needed to determine whether this drug will be protected by those who are not obese.”
